for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford BioMedica plc

OXB.L

Latest Trade

1,430.00GBp

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

774.33

 - 

1,554.20

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,430.00
Open
--
Volume
--
3M AVG Volume
2.71
Today's High
--
Today's Low
--
52 Week High
1,554.20
52 Week Low
774.33
Shares Out (MIL)
82.66
Market Cap (MIL)
1,182.00
Forward P/E
103.56
Dividend (Yield %)
--

Next Event

Half Year 2021 Oxford BioMedica PLC Earnings Release

Latest Developments

More

Oxford BioMedica Plc Says Andrew Heath Will Be Retiring As Non-Executive Director

Oxford Biomedica Upgrades Financial Guidance For Supply Agreement With AstraZeneca For Manufacture Of COVID-19 Vaccine

Oxford BioMedica FY Operating Loss 5.7 Million Stg

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oxford BioMedica plc

Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

Industry

Biotechnology & Drugs

Contact Info

Windrush Court, Transport Way

OX4 6LT

United Kingdom

+44.1865.783000

http://www.oxfordbiomedica.co.uk

Executive Leadership

Roch Frederic Doliveux

Non-Executive Chairman of the Board

John Dawson

Chief Executive Officer, Executive Director

Stuart Henderson

Deputy Chair and Senior Independent Non-Executive Director

Stuart Paynter

Chief Financial Officer, Executive Director

Nick Page

Chief Operating Officer

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (GBp)

2018

10.890

2019

-19.510

2020

-6.820

2021(E)

14.063
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.47
Price To Book (MRQ)
10.44
Price To Cash Flow (TTM)
328.88
Total Debt To Equity (MRQ)
12.28
LT Debt To Equity (MRQ)
8.31
Return on Investment (TTM)
-5.54
Return on Equity (TTM)
-4.07

Latest News

Latest News

AstraZeneca must use Britain's plant if needed to meet EU's vaccine commitments - EU lawyer

AstraZeneca must deliver COVID-19 vaccines to the European Union also from a factory in Britain if it is needed to meet its commitments with the EU, a judge ruled on Friday, according to a lawyer representing the EU.

Oxford Biomedica lifts outlook as AstraZeneca ramps up vaccine output

Oxford Biomedica on Tuesday doubled the revenue expectation from its COVID-19 vaccine supply deal with AstraZeneca after the drugmaker commissioned more batches from the company in the second half of 2021.

AstraZeneca bolsters COVID-19 vaccine supply with new deal

AstraZeneca has expanded its agreement with cell therapy firm Oxford Biomedica to mass-produce its COVID-19 potential vaccine, as it looks to scale-up supply ahead of a possible U.S. fast-track approval.

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a possible fast-track approval from the United States.

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm 15 million pounds ($20 million) upfront and an additional 35 million pounds plus other costs...

BRIEF-Oxford Biomedica Says Placing At 800p/Share Raising £40 Mln

* OXFORD BIOMEDICA - PLACING AT 800 PENCE PER/SHARE RAISING GROSS PROCEEDS OF £40 MILLION FOR CO, ABOUT £38.25 MILLION NET OF EXPENSES Source text for Eikon: Further company coverage:

BRIEF-PIRC Recommends A.G. Barr Shareholders To Vote Against Resolution To Approve Remuneration Policy

* PROXY ADVISORY FIRM PIRC RECOMMENDS A.G. BARR SHAREHOLDERS TO VOTE AGAINST RESOLUTION TO APPROVE REMUNERATION POLICY

BRIEF-Oxford Biomedica Announces Proposed Placing To Raise Up To £40 Mln

* OXFORD BIOMEDICA PLC - PROPOSED PLACING OF NEW ORDINARY SHARES

Oxford Biomedica eyes UK supply boost of AstraZeneca's COVID-19 vaccine

Oxford Biomedica has signed a new manufacturing agreement with a group backed by the UK government to help it scale up production of AstraZeneca's potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.

BRIEF-Oxford Biomedica Signs Collaboration Agreement With Vaccines Manufacturing and Innovation Centre

* OXFORD BIOMEDICA PLC - SIGNS FIVE YEAR COLLABORATION AGREEMENT WITH VACCINES MANUFACTURING AND INNOVATION CENTRE

Oxford Biomedica inks agreement to boost UK supply of AstraZeneca's COVID-19 vaccine

Gene and cell therapy firm Oxford Biomedica said on Monday it signed a new manufacturing agreement to help it scale up production of AstraZeneca's potential COVID-19 vaccine to cater to demand in the United Kingdom and Europe.

AstraZeneca scores twin drug approvals alongside vaccine progress

Britain's AstraZeneca has clinched expanded regulatory backing for two medications, including one for blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine.

Oxford Biomedica hires French pharma veteran after signing vaccine deal

Gene and cell therapy firm Oxford Biomedica plc said on Monday it had appointed French pharmaceutical industry veteran Roch Doliveux as its non-executive chairman, as it eyes a potentially major role in producing coronavirus vaccine.

BRIEF-Oxford BioMedica Says Roch Doliveux To Become Non-Exec Chairman Of Group

* OXFORD BIOMEDICA - ROCH DOLIVEUX WILL BECOME NON-EXECUTIVE CHAIRMAN OF GROUP WITH EFFECT FROM 24 JUNE 2020 Source text for Eikon: Further company coverage:

AstraZeneca picks Oxford Biomedica to make potential COVID-19 vaccine

AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses.

REFILE-Oxford BioMedica inks deal to make AstraZeneca's potential COVID-19 vaccine

Britain's Oxford BioMedica has agreed with AstraZeneca to manufacture the drugmaker's experimental COVID-19 vaccine, the cell therapy company said on Thursday.

BRIEF-Oxford Biomedica Signs Clinical & Commercial Supply Agreement With Astrazeneca UK

* OXFORD BIOMEDICA PLC - SIGNED A ONE YEAR CLINICAL & COMMERCIAL SUPPLY AGREEMENT WITH ASTRAZENECA UK LTD

BRIEF-Oxford Biomedica Receives Approval For First Two Oxbox Suites

* OXFORD BIOMEDICA PLC - OXB RECEIVES APPROVAL FOR FIRST TWO OXBOX SUITES Source text for Eikon: Further company coverage:

BRIEF-Oxford Biomedica Joins Consortium To Develop, Scale-Up And Manufacture Potential Vaccine Candidate For Covid-19

* JOINED CONSORTIUM TO RAPIDLY DEVELOP, SCALE-UP AND MANUFACTURE A POTENTIAL VACCINE CANDIDATE FOR COVID-19 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up